Rentaro Oda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rentaro Oda has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Igen Hongo
Division of Infectious Diseases, Musashino Red Cross Hospital, Japan
4 shared publicationsYoshiyuki Sekikawa
Division of Infectious Diseases, Musashino Red Cross Hospital, Japan
3 shared publicationsNorio Ohmagari
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
2 shared publicationsSatoshi Kutsuna
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Department of Infection Control, Graduate School of Medicine Faculty of Medicine, Osaka University, Osaka, Japan
2 shared publicationsAdam DeZure
1 shared publicationAkemi Yasuhara
Joint Center for Researchers, Associates and Clinicians Data Center, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 9 December 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (2) , 149-162
Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended‐Spectrum β‐lactamase producing Enterobacterales (ESBL‐E)
Study Objective: Establish methods for measuring cefmetazole (CMZ) concentrations conduct a pharmacokinetic/pharmacodynamic (PK/PD) analysis using unbound CMZ concentrations for extended‐spectrum β‐lactamase producing enterobacterales (ESBL‐E) and investigate optimal dosing regimens for not undergoing hemodialysis (non‐HD) and undergoing hemodialysis (HD) patients.Design: Prospective observational study.Patients: Included patients treated with CMZ who provided written informed consent and were admitted to the Tokyo Bay Urayasu Ichikawa Medical Center between August 2021 and July 2022.Measurements: Total and Unbound CMZ concentration was measured by high‐performance liquid chromatography (HPLC) with solid‐phase extraction and ultrafiltration.Setting: Determining the CMZ dosing regimen involved modified creatinine clearance (CLCR) with measured body weight (BW) using the Cockcroft–Gault equation. For non‐HD patients, blood samples were collected during at least three points. For patients undergoing HD, 1 g was administered via intravenous infusion, or rapid intravenous injection after HD, or 30 min before the end of HD. Blood samples were collected before HD (pre‐HD), and 1 and 3 h after starting HD and post‐HD. All blood samples were collected at steady‐state. Patient information was collected from electronic medical records. An unbound PK model was constructed for the non‐HD patients. A nomogram was constructed using Monte Carlo simulations with a 90% probability of target attainment at 70% free time above the minimum inhibitory concentration (MIC). For the HD patients, a nomogram was used to determine the optimal dosing regimen for each HD schedule.Main Results: CMZ measurement methods were established. A model analysis of unbound PK in 37 non‐HD patients incorporated creatinine clearance (CLCR) using the Cockcroft–Gault equation, albumin (ALB) for clearance and body weight (BW) for the volume of distribution. In Monte Carlo simulations, nomograms corresponding to the MIC (known and unknown) were generated for each covariate. Using the nomogram, non‐HD patients with an ESBL‐E MIC of 8 mg/L, a BW of 60 kg, an ALB of 25 g/L, and a CLCR of 60 mL/min required administration of 2 g every 6 h (1‐ and 3‐h infusions). Unbound PK model parameters were calculated for 7 HD patients, and the optimal dosing regimens following PK/PD were determined for each HD schedule. In HD patients, the regimen after and during HD was established using a treatment that was effective up to an ESBL‐E MIC of 4 mg/L.Conclusions: The nomogram for CMZ regimens established by PK/PD analysis of measured CMZ concentrations enables optimal CMZ dosing for ESBL‐E‐infected patients.
- 9 December 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (2) , 149-162
Open AccessPharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended‐Spectrum β‐lactamase producing Enterobacterales (ESBL‐E)
Study Objective: Establish methods for measuring cefmetazole (CMZ) concentrations conduct a pharmacokinetic/pharmacodynamic (PK/PD) analysis using unbound CMZ concentrations for extended‐spectrum β‐lactamase producing enterobacterales (ESBL‐E) and investigate optimal dosing regimens for not undergoing hemodialysis (non‐HD) and undergoing hemodialysis (HD) patients.Design: Prospective observational study.Patients: Included patients treated with CMZ who provided written informed consent and were admitted to the Tokyo Bay Urayasu Ichikawa Medical Center between August 2021 and July 2022.Measurements: Total and Unbound CMZ concentration was measured by high‐performance liquid chromatography (HPLC) with solid‐phase extraction and ultrafiltration.Setting: Determining the CMZ dosing regimen involved modified creatinine clearance (CLCR) with measured body weight (BW) using the Cockcroft–Gault equation. For non‐HD patients, blood samples were collected during at least three points. For patients undergoing HD, 1 g was administered via intravenous infusion, or rapid intravenous injection after HD, or 30 min before the end of HD. Blood samples were collected before HD (pre‐HD), and 1 and 3 h after starting HD and post‐HD. All blood samples were collected at steady‐state. Patient information was collected from electronic medical records. An unbound PK model was constructed for the non‐HD patients. A nomogram was constructed using Monte Carlo simulations with a 90% probability of target attainment at 70% free time above the minimum inhibitory concentration (MIC). For the HD patients, a nomogram was used to determine the optimal dosing regimen for each HD schedule.Main Results: CMZ measurement methods were established. A model analysis of unbound PK in 37 non‐HD patients incorporated creatinine clearance (CLCR) using the Cockcroft–Gault equation, albumin (ALB) for clearance and body weight (BW) for the volume of distribution. In Monte Carlo simulations, nomograms corresponding to the MIC (known and unknown) were generated for each covariate. Using the nomogram, non‐HD patients with an ESBL‐E MIC of 8 mg/L, a BW of 60 kg, an ALB of 25 g/L, and a CLCR of 60 mL/min required administration of 2 g every 6 h (1‐ and 3‐h infusions). Unbound PK model parameters were calculated for 7 HD patients, and the optimal dosing regimens following PK/PD were determined for each HD schedule. In HD patients, the regimen after and during HD was established using a treatment that was effective up to an ESBL‐E MIC of 4 mg/L.Conclusions: The nomogram for CMZ regimens established by PK/PD analysis of measured CMZ concentrations enables optimal CMZ dosing for ESBL‐E‐infected patients.
- 11 May 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (9) , 869-874
Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial
- 11 May 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (9) , 869-874
Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial
- Top Cited Papers
- 11 June 2020
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (24) , 2327-2336
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)
- 11 June 2020
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (24) , 2327-2336
Top Cited PapersCompassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)
- 1 May 2017
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 23 (5) , 333-335
The first case of imported Borrelia miyamotoi disease concurrent with Lyme disease
- 1 May 2017
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 23 (5) , 333-335
The first case of imported Borrelia miyamotoi disease concurrent with Lyme disease
- Open Access
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (24) , 3403-3404
Meningococcal Bursitis
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (24) , 3403-3404
Open AccessMeningococcal Bursitis
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (15) , 2083
The Diagnosis of Secondary Syphilis by Gram and Giemsa Staining
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (15) , 2083
Open AccessThe Diagnosis of Secondary Syphilis by Gram and Giemsa Staining
- Open Access
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (4) , 469-470
Primary Cutaneous Nocardiosis in an Immunocompetent Patient
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (4) , 469-470
Open AccessPrimary Cutaneous Nocardiosis in an Immunocompetent Patient